Glioblastoma Drug Development Summit 2019

Glioblastoma Drug Development Summit is organized by Hanson Wade and will be held from Dec 10 - 11, 2019 at The Westin Boston Waterfront, Boston, Massachusetts, United States of America.

Description:
This Conference is designed with two critical and ambitious objectives - to help you:
• Overcome the major biological challenges limiting effective Glioblastoma treatment
• Evaluate novel therapies and innovative trial design to prevent more tragic phase 2 failures

Glioblastoma is a notoriously aggressive cancer and remains a huge unmet medical need. The inaugural Glioblastoma Drug Development Summit is the first and only dedicated conference for large pharma, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery, translation and clinical development of safe, effective and deliverable therapies to treat glioblastoma.

Gain exclusive insights into tackling specific and applied drug development challenges limiting effective therapies. This includes tumour heterogeneity, redundant pathway signalling, the immunosuppressive tumour environment and penetration through the blood-brain barrier.

This meeting provides a platform for acute feedback and discussions aimed specifically at helping you not only successfully translate drug candidates into human clinical trials, but optimize the clinical development itself to avoid more clinical failures.

With 60+ thought-leaders converging at the first industry led Glioblastoma Drug Development Summit, this is an unrivalled opportunity for you to gain the latest scientific insights with renowned neuro-oncologists and join those striving to advance safe and effective therapeutic breakthroughs to patients in need.

Additional details will be posted as soon as information is available.